Brean Capital Reaffirms “Buy” Rating for TG Therapeutics Inc. (TGTX)
TG Therapeutics Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating restated by equities researchers at Brean Capital in a report issued on Thursday. They currently have a $28.00 price objective on the biopharmaceutical company’s stock. Brean Capital’s price objective would suggest a potential upside of 224.07% from the company’s previous close.
Other equities analysts also recently issued research reports about the company. Roth Capital reaffirmed a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a research report on Thursday, June 9th. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Monday, June 13th. Zacks Investment Research downgraded TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 14th. Finally, S&P Equity Research cut their price objective on TG Therapeutics from $7.15 to $6.40 in a research report on Wednesday, August 24th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $20.81.
TG Therapeutics (NASDAQ:TGTX) opened at 8.64 on Thursday. The firm has a 50-day moving average price of $7.15 and a 200-day moving average price of $7.38. The stock’s market cap is $470.50 million. TG Therapeutics has a 12 month low of $5.41 and a 12 month high of $14.87.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative net margin of 40,142.11% and a negative return on equity of 58.77%. Equities research analysts expect that TG Therapeutics will post ($1.22) earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of TGTX. BlackRock Advisors LLC increased its position in TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 2,296 shares during the last quarter. Mariner Wealth Advisors LLC increased its position in TG Therapeutics by 4.4% in the second quarter. Mariner Wealth Advisors LLC now owns 19,086 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 800 shares during the last quarter. SECOR Capital Advisors LP purchased a new position in TG Therapeutics during the second quarter worth about $187,000. Emerald Acquisition Ltd. purchased a new position in TG Therapeutics during the second quarter worth about $190,000. Finally, Rhumbline Advisers increased its position in TG Therapeutics by 9.0% in the second quarter. Rhumbline Advisers now owns 37,547 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 3,107 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.